Scientists have announced a significant breakthrough in fertility research, claiming to have 'rejuvenated' human eggs for the first time. This advance, which could substantially boost IVF success rates, particularly for older women, involves supplementing eggs with a crucial protein. Researchers, led by Professor Melina Schuh from the Max Planck Institute for Multidisciplinary Sciences in Göttingen and co-founder of Ovo Labs, discovered that an age-related decline in a protein called Shugoshin 1 contributes to genetic errors, specifically chromosomal abnormalities, in older eggs. These errors are a primary cause of IVF failure and miscarriage as women age. In laboratory experiments using eggs donated by fertility patients, microinjections of Shugoshin 1 drastically reduced the incidence of these defects, almost halving the number of eggs with abnormal chromosomes (from 53% to 29% in treated eggs). This technique addresses a critical problem in reproductive medicine, as current IVF success rates for women aged 43-44 are as low as 5%, compared to 35% for those under 35. The findings were presented at the British Fertility Conference in Edinburgh and published as a preprint on the Biorxiv website, indicating peer review and scientific scrutiny. While the results are promising, researchers emphasize that more extensive trials are needed to confirm the approach's effectiveness and safety before it can be widely commercialized by companies like Ovo Labs. This development offers considerable hope for individuals and couples in India and globally struggling with age-related infertility, potentially making IVF a more viable option.